RT Journal Article
T1 Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review).
A1 Martino, Alessandro
A1 Sainz, Juan
A1 Buda, Gabriele
A1 Jamroziak, Krzysztof
A1 Reis, Rui Manuel
A1 García-Sanz, Ramón
A1 Jurado, Manuel
A1 Ríos, Rafael
A1 Szemraj-Rogucka, Zofia
A1 Marques, Herlander
A1 Lesueur, Fabienne
A1 Moreno, Victor
A1 Orciuolo, Enrico
A1 Gemignani, Federica
A1 Landi, Stefano
A1 Rossi, Anna Maria
A1 Dumontet, Charles
A1 Petrini, Mario
A1 Campa, Daniele
A1 Canzian, Federico
K1 IMMEnSE consortium,
K1 Multiple myeloma
K1 SNPs
K1 Genetic susceptibility
K1 Hharmacogenetics
K1 Humanos
K1 Variación Genética
K1 Farmacogenética
K1 Factores de Riesg0
K1 Mieloma Múltiple
K1 Epidemiología Molecular
AB There is strong evidence suggesting the presence of a genetic component in the aetiology of multiple myeloma (MM). However no genetic risk factors have been unequivocally established so far. To further our understanding of the genetic determinants of MM risk, a promising strategy is to collect a large set of patients in a consortium, as successfully done for other cancers. In this article, we review the main findings in the genetic susceptibility and pharmacogenetics of MM and present the strategy of the IMMEnSE (International Multiple Myeloma rESEarch) consortium in contributing to determine the role of genetic variation in pharmacogenetics and in MM risk.
PB Spandidos Publications
SN 1019-6439
YR 2012
FD 2012-03
LK http://hdl.handle.net/10668/1379
UL http://hdl.handle.net/10668/1379
LA en
NO Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, et al. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int. J. Oncol. 2012; 40(3):625-38
NO Journal Article; Research Support, Non-U.S. Gov't; Review;
DS RISalud
RD Apr 19, 2025